Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Inhibrx Inc (INBX)

Inhibrx Inc (INBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

INBX : 24.68 (+0.90%)
Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

INBX : 24.68 (+0.90%)
FULC : 7.82 (-7.02%)
Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported...

INBX : 24.68 (+0.90%)
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -80% and 4.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

GH : 55.04 (+1.59%)
INBX : 24.68 (+0.90%)
JMP Securities Thinks Inhibrx’s Stock is Going to Recover

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Inhibrx (INBX – Research Report) today and set a price target of $40.00. The company's shares closed last Tuesday at $13.78, close to its...

INBX : 24.68 (+0.90%)
Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

INBX : 24.68 (+0.90%)
RNA : 22.21 (+1.18%)
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CARA : 11.75 (+2.09%)
INBX : 24.68 (+0.90%)
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates

KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of 34.69% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

HGEN : 0.3832 (+5.56%)
INBX : 24.68 (+0.90%)
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?

Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

INBX : 24.68 (+0.90%)
CRMD : 4.13 (-0.48%)
Oversold Conditions For Inhibrx (INBX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

INBX : 24.68 (+0.90%)

Barchart Exclusives

100% Buy Alert Flashing For This Fintech Giant
Looking for buy alerts? This company has been around since 1949 and is flashing 100% buy signals across the board. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar